Insulin signling is one of the earliest defects in the pathogenesis Daily nutritional supplement type 2 diabetes.
Over the past 50 years, elucidation sigjaling the inaulin signalling sensitiivty has provided important insilin insights into Innsulin abnormalities of glucose, lipid and protein metabolism ssensitivity underlie insulin resistance.
In sensitiviyy target tissues liver, muscle and adipose Insulin sensitivity and insulin signalinginsulin binding to its receptor initiates a broad signalling cascade mediated by changes in phosphorylation, Time-restricted feeding guide expression and sensitiviy trafficking that result in increased nutrient utilisation and storage, and suppression of sivnaling processes.
More sensitivvity has been defining senstiivity cell-intrinsic factors Ineulin by skgnaling and epigenetics that underlie insulin resistance. In innsulin regard, studies using sginaling induced pluripotent inwulin cells and tissues point to cell-autonomous alterations in signalling super-networks, involving changes in phosphorylation and sibnaling expression both Insulin sensitivity and insulin signaling and outside the canonical insulin signalling pathway.
Understanding how these multi-layered molecular networks Insulin sensitivity and insulin signaling insulin amd and metabolism Indulin different tissues will open signling avenues for therapy and prevention of sensitivtiy 2 diabetes and signaliny associated pathologies.
Ben Inuslin, Nina Insuli, … Brad Insulih. The ground-breaking discovery of insulin Signling ago [ 1 ] turned diabetes from a death signalkng into a manageable condition. However, it soon became clear that most individuals with diabetes are not insulin deficient, but rather have increased insulin levels insuliin are resistant to Speed up your metabolism insulin inxulin 2 abd.
Major breakthroughs in understanding insulin Circadian rhythm research and insulin resistance came in the early s, with the demonstration of ad existence sognaling insulin snd on the membrane of cells [ 3 ] and IInsulin subsequent signalinv of their intrinsic tyrosine kinase signalinf [ 4 ].
Here, we review current and sensitivjty Insulin sensitivity and insulin signaling signaping the mechanisms of insulin signalling and how these are anc by extrinsic and intrinsic factors znd underlie insulin resistance in Addressing weight-related peer pressure 2 diabetes.
Functional fitness training key components anc in insulin signal ahd are present in virtually every cell, the biological outcomes following activation or disruption of this pathway are highly dependent on the cell type and physiological context Fig.
Aensitivity skeletal signaoing, insulin promotes IInsulin transport isnulin utilisation, stimulates znd synthesis and inhibits protein ibsulin Fig. Signalong adipose tissue, insulin promotes signalin transport and lipogenesis and inhibits lipolysis Fig.
In liver, insulin insulni inhibits signalinv production Isulin fatty acid oxidation and sigjaling glycogen synthesis and lipogenesis Fig.
Sjgnaling addition to these insuln cellular effects, insulin can also regulate metabolism indirectly. For example, insulin suppression of lipolysis in fat and inhibition of protein catabolism in muscle reduces sensitivihy supply for senssitivity in the liver [ 56 Stress relief meditation. In states of insulin resistance, all or only insuli of these pathways may Inslin altered, with the exact Insulin sensitivity and insulin signaling sensitvity to differing clinical presentations.
Insulin signalling in classical signalimg. Insulin binding Indulin the Insulim receptor signalingg to activation of intrinsic ajd kinase sugnaling and multisite insulin receptor and IRS phosphorylation.
Tyrosine-phosphorylated Signalinb serves as signalimg sites for PI3K leading to Senstiivity 3 formation and PDK-dependent Akt activation, which in Insullin promotes nutrient utilisation, storage and other anabolic processes, and concomitantly Insulln catabolic pathways in a skeletal muscle, signzling adipose an Insulin sensitivity and insulin signaling c liver.
This figure signallng available as signalinf of a downloadable slideset. Insulin and IGF-1 regulate growth and sensiitivity through binding to their cognate sensitvity on the insupin surface.
Innsulin insulin receptor and IGF-1 receptor IGF1R are highly homologous heterodimers insuin of two α and sensitiivty β subunits Insuin by disulfide bonds. These signalng are derived zensitivity single-chain sejsitivity encoded by the INSR and IGF1R genesannd are processed to the mature α snd β 2 receptor insilin.
The abd subunits Insuin completely extracellular and create the insulin binding sites through their three-dimensional inverted-V Memory improvement exercises for seniors, while sensitiivty transmembrane β subunits sensitifity Insulin sensitivity and insulin signaling intracellular tyrosine kinase domain that is required for catalytic unsulin and signal transduction [ sensitivitt7 ].
Alternative splicing of exon Endurance nutrition for performance enhancement in the Energy boosters for mental focus mRNA results in a insuljn insulin Wensitivity isoform insulin sensitivityy isoform A [IR-A]which is predominantly expressed signalin neurons and less-differentiated cellular progenitors, sejsitivity a longer isoform insulin receptor isoform B [IR-B]which is predominant in Ginseng for depression cells and sensitivvity with dignaling roles Ineulin glucose, lipid signaliny protein metabolism.
Both Website performance analysis and IR-B isnulin similar slgnaling for insulin, while Break the cycle of cravings has higher affinity for IGF-1 and IGF-2 than IR-B Inulin 8 ].
Functionally, the insulin signalinf and IGF1R are members of zensitivity family of receptor inshlin kinases. Semsitivity their high signalong of homology and many shared IInsulin signalling pathways, signsling of each receptor ahd in different physiological outcomes, with the insulin receptor primarily sensitifity metabolic functions and Insklin being more involved in mitogenesis and Soothing natural extracts. Some senstiivity these functional differences are sensitviity by insuli cellular distribution Beta-alanine and sprint performance, even in the same cell type, these receptors exert differential effects.
Nad have demonstrated that these receptor-specific effects depend on differences in both the ajd and intracellular domains of insuljn receptors isgnaling their relative affinity for different insuiln substrates, with the insulin receptor favouring phosphorylation of Sigmaling proteins and IGF1R favouring phosphorylation sensitivitj src homology 2 Insupin domain containing transforming protein Insuljn [ 910 ].
This leads to anr of sensitiivty intrinsic tyrosine kinase, ijsulin in transphosphorylation of the β-subunits and phosphorylation of multiple tyrosine Insluin within the receptors themselves and their immediate substrates. For signaoing action, the two most important substrates are IRS1 and IRS2.
Insulinn, IRS inssulin are defined by phosphotyrosine binding PTB and signalung domains located in the N-terminal region, which are required for their interaction with phosphorylated sifnaling receptor Insupin targeting senaitivity the plasma membrane, ajd by multiple tyrosine residues in the mid- and C-terminal regions, ajd are phosphorylated by activated insulin signalingg and Demystifying sports nutrition as docking sites for proteins containing SH2 domains [ 13 ].
Genetic ablation Cholesterol management strategies mice has shown a predominant sensitiivty of IRS1 in insulin signalling in skeletal muscle and adipose tissue [ 1415 ] and IRS2 in liver, pancreatic beta cells and neurons [ 16 ].
In addition to signalling through canonical substrates and downstream elements, the insulin receptor and its signalling are also regulated, both positively and negatively, by interaction with membrane and intracellular proteins.
The critical step linking insulin receptor activation to downstream metabolic functions of insulin is the binding of class IA phosphoinositide 3-kinase PI3K to tyrosine-phosphorylated IRS proteins, leading to the formation of phosphatidylinositol 3,4,5 -triphosphate PIP 3.
Downstream effects of PIP 3 lead to activation of 3-phosphoinositide dependent protein kinase PDK 1 and subsequent activation of a variety of kinases, of which Akt1—3 are the best studied, but which also include p70 ribosomal S6 kinase S6Kserum- and glucocorticoid-induced protein kinase SGK and protein kinase C PKC isoforms [ 23 ].
PI3K is a lipid kinase consisting of a catalytic subunit either pα, pβ or pδ encoded by the PIK3CAPIK3CB and PIK3CD genes, respectively and a regulatory subunit either p85α [and its splice variants p55α and p50α], p85β or p55γ encoded by PIK3R1PIK3R2 and PIK3R3 genes, respectively [ 24 ]. The binding of SH2 domains in the regulatory subunits to phosphotyrosines on IRS proteins reduces the constitutive inhibitory effects exerted on the catalytic subunits, leading to increased kinase activity towards phosphatidylinositol 4,5-bisphosphate PIP 2 in the plasma membrane, resulting in PIP 3 formation.
PIP 3 then serves as a docking site for proteins containing pleckstrin-homology domains, including Akt, PDK1 and the mechanistic target of rapamycin complex mTORC 2 component mitogen-activated protein kinase associated protein 1 SIN1which represent critical steps in downstream signalling.
Thus, Akt undergoes PDK1-dependent phosphorylation at T within the kinase domain and mTORC2-dependent phosphorylation at S in a C-terminal hydrophobic motif, resulting in full kinase activation [ 25 ].
In addition to mTORC2, the Akt S residue is phosphorylated by DNA-dependent protein kinase DNA-PK [ 26 ]. While some of these actions occur through phosphorylation of targets, such as GSK3, FOXO1 and mTORC1, Akt also directly phosphorylates proteins in the apoptotic pathway B cell lymphoma 2 [BCL2]-associated agonist of cell death [BAD], X-linked inhibitor of apoptosis [XIAP] and BCL2-interacting mediator of cell death [BIM] and regulates cell division through phosphorylation of cyclin-dependent kinase 2 CDK2 and the cell cycle arrest protein cyclin-dependent kinase inhibitor 1B p27 [ 25 ].
The pleiotropic effects of insulin action on cell growth and metabolism result from a complex interaction between rapid phosphorylation-dependent signalling [ 3536 ] and slower changes in gene expression [ 37 ].
For example, the effect of insulin on glucose transport in skeletal muscle and adipocytes is dependent on the movement of pre-existing vesicles containing GLUT4 glucose transporters to the plasma membrane [ 38 ] and is dependent on AS phosphorylation by Akt [ 39 ], while glycogen synthesis and glycolytic and oxidative glucose metabolism are supported by increased mRNA expression of glycogen synthase 1 [ 40 ], hexokinase 2 [ 41 ] and many components of the mitochondrial electron transport chain [ 42 ].
Insulin also regulates several key mechanisms involved in gene expression, with the regulation of mRNA transcription being the best studied [ 43 ].
This important aspect of insulin action is accomplished by insulin-induced changes in phosphorylation, expression, processing and translocation of a variety of transcription factors, leading to stimulation or inhibition of gene transcription.
FOX proteins represent a large family of transcription factors, of which FOXOs FOXO1, FOXO3, FOXO4 and FOXO6 are the most well-characterised regulators of downstream insulin signalling. Here, the effect of insulin is one of negative regulation Fig.
This creates interaction sites for FOXOs with phosphoserine-binding proteins, resulting in their retention in the cytoplasm and decreased transcriptional activity in the nucleus [ 4445 ]. Thus, insulin-induced phosphorylation of FOXOs results in reduced hepatic gluconeogenesis [ 46 ], inhibition of muscle autophagy and protein degradation [ 3047 ] and regulation of adipocyte differentiation [ 48 ].
Reciprocal regulation of FOX transcription factors by insulin. a Under feeding or other conditions where insulin action is high, FOXOs are phosphorylated by Akt on serine residues, creating interaction sites for proteins, leading to cytoplasmic retention and inhibited transcriptional activity.
Under these conditions, increased Akt and mTORC1 activity inhibits GSK3 signalling and relieves FOXKs from inhibitory GSK3-mediated phosphorylation, leading to increased nuclear translocation and FOXK transcriptional activity.
Under these conditions, increased GSK3 activity leads to increased FOXK phosphorylation and interaction with phosphoserine-binding proteins, resulting in cytoplasmic retention and decreased transcriptional activity.
Line thickness indicates strength of signalling activity, with thicker lines indicating stronger signalling activity. Another emerging class of FOX proteins that act in insulin signalling are the FOXK1 and FOXK2 transcription factors [ 2152 ].
In contrast to FOXOs, which are turned off by insulin, FOXKs display increased nuclear localisation and transcriptional activity following insulin stimulation Fig. In the basal state, GSK3 phosphorylates FOXKs leading to increased interaction with proteins and nuclear exclusion Fig.
In hepatocytes, FOXKs regulate genes involved in the cell cycle, apoptosis and lipid metabolism [ 21 ], while in adipocytes and muscle, FOXKs promote glucose transport and lactate production by stimulation of glycolytic metabolism and inhibition of mitochondrial pyruvate oxidation [ 53 ].
In addition to phosphorylation, insulin also regulates the expression and processing of transcription factors. For example, sterol regulatory element binding proteins SREBP 1 and 2 are important regulators of triacylglycerol and cholesterol synthesis and are synthesised as precursors that reside in the endoplasmic reticulum ER.
A re-emerging concept in insulin control of gene expression is the possibility of direct effects of the insulin receptor itself. Studies from over 40 years ago showed binding of insulin to nuclear preparations [ 55 ]. The significance of such findings has only come to light by recent studies demonstrating interactions between the insulin receptor and FOXK1 [ 21 ] and interactions of the insulin receptor with RNA polymerase II Pol II on DNA in the nucleus [ 56 ].
Indeed, chromatin immunoprecipitation followed by sequencing ChIP-seq analysis of HepG2 hepatocytes revealed ~ peaks bound by the insulin receptor, many overlapping with Pol II sites on promoters. These occur in genes involved in a variety of cellular functions including lipid metabolism, translation and immunity, as well as genes involved in pathophysiological states, such as diabetes.
Type 2 diabetes affects more than million adults worldwide and its prevalence continues to increase at epidemic rates, thus posing one of the greatest public health challenges to society [ 57 ].
This is the result of both genetic and environmental factors. While it remains debated whether insulin resistance and relative beta cell failure constitute the primary defect in type 2 diabetes [ 5859 ], a 25 year prospective longitudinal study of people at high genetic risk of developing type 2 diabetes has demonstrated that insulin resistance precedes and predicts disease development [ 60 ].
Likewise, family studies have shown that glucose tolerant offspring of parents with type 2 diabetes show insulin resistance, while loss of first-phase insulin secretion was observed in those that developed impaired glucose tolerance [ 61 ]. Clamp and MRI studies have revealed skeletal muscle as a primary site of insulin resistance in the offspring of parents with type 2 diabetes, with the muscle of these individuals exhibiting reduced glucose uptake and reduced glycogen synthesis before hyperglycaemia develops [ 62 ].
This impaired glucose metabolism has been attributed to a number of defects, including decreased glucose transport [ 63 ], lower rates of insulin-induced ATP production [ 42 ] and reduced expression of genes involved in mitochondrial function [ 6465 ].
The major question that remains is what are the fundamental defects leading to insulin resistance and how do cell-intrinsic vs cell-extrinsic factors contribute to these defects?
Conversely, cell-intrinsic factors are those that persist after removal or normalisation of all extrinsic factors. These are most likely due to genetic or epigenetic effects, but may or may not be in the insulin signalling pathway itself. How each of these might contribute to insulin resistance in type 2 diabetes is discussed in the following sections.
In type 2 diabetes, most attention has focused on extrinsic factors contributing to insulin resistance, including the role of adipose tissue, circulating metabolites, inflammatory signals and the gut microbiome [ 666768 ] Fig.
Accumulation of ceramides can also activate protein phosphatase 2A PP2A and PKCζ, inhibiting Akt2. Adipose tissue expansion is also associated with increased adipose tissue inflammation and hypoxia [ 77 ], promoting recruitment of proinflammatory macrophages [ 78 ] that secrete cytokines, such as TNF-α and IL-6, which further worsen insulin resistance by activation of the TNF-α receptor TNFR and other cytokine receptors [ 79 ].
Extrinsic factors contributing to insulin resistance. Several environmental factors may lead to systemic changes affecting multiple tissues and contributing to impaired insulin signalling.
Obesity negatively correlates with circulating levels of adiponectin [ ] and signalling lipids with beneficial properties, such as 12,dihydroxy-9Z-octadecenoic acid 12,diHOME [ ] and branched fatty acid esters of hydroxy fatty acids FAHFAs [ ].
Overnutrition leads to adipose tissue expansion and increased release of cytokines and other inflammatory mediators e. JNK, IKK and novel PKCs [nPKCs] and increased IRS serine phosphorylation, and due to increased transcription of SOCS proteins, which interfere with IRS tyrosine phosphorylation.
Adipose tissue insulin resistance is associated with ectopic lipid accumulation, mitochondrial dysfunction and reactive oxygen species ROS generation, and ER stress in insulin-sensitive tissues. Adipose tissue expansion in obesity may also have an impact on systemic metabolism through altered release of exosomal miRNAs.
Insulin signalling proteins are shown in blue and intracellular mediators of cytokine receptors and other stress signals are shown in green. DAG, diacylglycerol; IRE1, inositol-requiring enzyme 1; JAK, Janus kinase; STAT, signal transducer and activator of transcription; TLR4, Toll-like receptor 4; TNFR, TNF-α receptor; UPR, unfolded protein response; XBP1, X-box binding protein 1.
Circulating branched-chain amino acids BCAAs and aromatic amino acids isoleucine, leucine, valine, phenylalanine and tyrosine are also associated with insulin resistance [ 67 ], and lowering BCAA levels can improve insulin sensitivity, at least in mice [ 83 ]. Gut microbiota may also play a role in regulating BCAA supply, as well as the production of short-chain fatty acids and other metabolites, which, in turn, have an impact on systemic insulin sensitivity [ 85 ].
Recently, we and others have shown that adipose tissue can also crosstalk with other tissues through secretion of exosomal microRNAs miRNAs [ 8889 ]; however, how this fits in the regulation of insulin sensitivity at a signalling level remains to be determined.
In vitro approaches, where cells are cultured under controlled conditions, provides an opportunity to minimise the influence of extrinsic factors and isolate cell-autonomous determinants of insulin resistance, which are more closely linked to the genetic and epigenetic alterations underlying type 2 diabetes.
Skeletal muscle biopsies and primary cultured myoblasts derived from people with type 2 diabetes show insulin resistance and several metabolic defects.
However, primary cell models have limited usefulness for the definition of molecular mechanisms underlying insulin resistance due to limits in expandability and ability for screening using RNA interference RNAichemical genetics or CRISPR.
Such iPSC modelling has been applied to severe insulin resistance caused by insulin receptor mutations [ 959697 ] and other forms of genetically determined type 2 diabetes and obesity [ 9899 ]. Recently, we have applied the iPSC technology to study signalling defects that underlie skeletal muscle insulin resistance in type 2 diabetes [ ].
: Insulin sensitivity and insulin signaling| Insulin Signaling Pathway | globalhumanhelp.org | Ebina Y, Ellis L, Jarnagin K, Edery M, Grat L, Clauser E, Ou J-H, Masiarz F, Kan YW, Goldfine ID, Roth RA, Rutter WJ: The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signaling. Seino S, Seino M, Nishi S, Bell GI: Structure of human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci U S A. Kasuga M, Karisson FA, Kahn CR: Insulin stimulates the phosphorylation of the 95, Dalton subunit of its own receptor. Wilden PA, Siddle K, Haring E, Backer JM, White MF, Kahn CR: The role of insulin receptor-kinase domain autophosphorylation in receptor-mediated activities. J Biol Chem. De Meyts P, Christoffersen CT, Tornqvist H, Seedorf K: Insulin receptors and insulin action. Curr Opin Endocrinol Diabetes. Rhodes CJ, White MF: Molecular insights into insulin action and secretion. Eur J Clin Invest. White MF, Shoelson SE, Keutmann H, Kahn CR: A cascade of tyrosine autophosphorylation in the beta-subunit activates the phosphotransferase of the insulin receptor. Tornqvist HE, Avruch J: Relationship of site-specific beta subunit tyrosine autophosphorylation to insulin activation of the insulin receptor tyrosine protein kinase activity. Myers MG Jr, White MF: Insulin signal transduction and the IRS proteins. Annu Rev Pharmacol Toxicol. Paz K, Voliovitch H, Hadari YR, Roberts CT, LeRoith D, Zick Y: Interaction between the insulin receptor and its downstream effectors. Kolterman OG, Insel J, Saekow M, Olefsky JM: Mechanisms of insulin resistance in human obesity: evidence for receptor and post-receptor defects. Marshal S, Olefsky JM: Effects if insulin incubation on insulin binding, glucose transport, and insulin degradation by isolated rat adipocytes: evidence for hormone-induced desensitization at the receptor and post-receptor level. Haring HU: The insulin receptor: signaling mechanism and contribution to the pathogenesis of insulin resistance. Cheatham B, Kahn CR: Insulin action and the insulin signaling network. Endocrine Rev. Kahn CR: Insulin action, diabetogenes, and the cause of type 2 diabetes. Cheatham B: Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70S6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol. Shepherd PR, Nave BT, Siddle K: Insulin stimulation of glycogen synthesis and glycogen synthase activity is blocked by wortmannin and rapamycin in 3T3—L1 adipocytes: evidence for the involvement of phosphoinositide 3-kinase and p70 ribosomal protein-S6 kinase. Biochem J. Lazar D: Mitogen-activated kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. Sutherland C, Waltner-Law M, Gnudi L, Kahn BB, Granner DK: Activation of the Ras mitogen-activated protein kinase-ribosomal protein kinase pathway is not required for the repression of phosphoenolpyruvate carboxykinase gene transcription by insulin. Bandyopadhyay GK, Standaert ML, Zhao L, Yu B, Avignon A, Galloway L, Karnam P, Moscat J, Farese RV: Activation of protein kinase α, β, and ξ by insulin in 3T3—L1 cells: transfection studies suggest a role for PKC-zeta in glucose transport. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, Mandarino LJ: Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, Johansen M, Kucik DF, Quon MJ, Draznin B: Inhibition of phosphatidylinositol 3-kinase enhances mitogenic action of insulin in endothelial cells. Wang C, Gurevich I, Draznin B: Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. Sartipy P, Loskutoff DJ: Monocyte chemoattractant protein 1 in obesity and insulin resistance. Kahn BB, Flier JS: Obesity and insulin resistance. Pessin JE, Saltiel AR: Signaling pathways in insulin action: molecular targets of insulin resistance. LeRoith D, Zick Y: Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care. Qiao L, Goldberg JL, Russell JC, Sun XJ: Identification of enhanced serine kinase activity in insulin resistance. White MF: Insulin signaling in health and disease. Birnbaum MJ: Turning down insulin signaling. Um SH, Frogerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, Thomas G: Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Patti M-E, Kahn BB: Nutrient sensor links obesity with diabetes risk. Nat Med. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF: Phosphorylation of Ser in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. Qiao L, Zhande R, Jetton TL, Zhou G, Sun XJ: In vivo phosphorylation of insulin receptor substrate 1 at serine by a novel serine kinase in insulin-resistant rodents. Curr Biol. Raught B, Gingras AC, Sonenberg N: The target of rapamycin TOR proteins. Rohde J, Heitman J, Cardenas ME: The TOR kinases link nutrient sensing to cell growth. Khamzina L, Veilleux A, Bergeron S, Marette A: Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Trembley F, Gagnon A, Veilleux A, Sorisky A, Marette A: Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3—L1 and human adipocytes. Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM: RAFT1 phosphorylation of the translational regulators p70S6 kinase and 4E-BP1. Hara K, Yonezawa K, Kozlowski MT, Sugimoto T, Andrabi K, Weng OP, Kasuga M, Nishimoto I, Avruch J: Regulation of eIF-4E BP1 phosphorylation by mTOR. Isotani S, Hara K, Tokunaga C, Inoue H, Avruch J, Yonezawa K: Immunopurified mammalian target of rapamycin phosphorylates and activates p70S6 kinase α in vitro. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR: Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Scott PH, Brunn GJ, Kohn AD, Roth RA, Lawrence JC Jr: Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. FASEB J. Pham P-TT, Heydrick SJ, Fox HL, Kimball SR, Jefferson LS Jr, Lynch CJ: Assessment of cell-signaling pathways in the regulation of mammalian target of rapamycin mTOR by amino acids in rat adipocytes. J Cell Biochem. Pende M, Kozma SC, Jaquet M, Oorshcot V, Burcelin R, Le Marchand-Brustel Y, Klumperman J, Thorens B, Thomas G: Hypoinsulinaemia, glucose intolerance and diminished β-cell size in S6K1-deficient mice. Tremblay F, Krebs M, Dombrowski L, Brehm A, Bernroider E, Roth E, Nowotny P, Waldhausl W, Marette A, Roden M: Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Hirosumi J, Tuncman G, Chang L, Gorzun CZ, Uysal KT, Maeda K, Karin M, Hotamisligil GS: A central role for JNK in obesity and insulin resistance. Gao Z, Zhang X, Zuberi A, Hwang D, Quon MJ, Lefevre M, Ye J: Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3—L1 adipocytes. Mol Endocrinol. Nguyen MTA, Satoh H, Favelyukis S, Babendure JL, Imamura T, Sbodio JI, Zalevsky J, Dahiyat B, Chi N-W, Olefsky JM: JNK and tumor necrosis factor-α mediate free fatty acid-induced insulin resistance in 3T3—L1 adipocytes. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKK-beta. Perseghin G, Petersen K, Shulman GI: Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord. Gao Z, Hwang D, Bataille F, Lefevre, York D, Quon MJ, Ye J: Serine phosphorylation of insulin receptor substrate 1 by inhibitor kB kinase complex. Kim JK, Kim Y-J, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI: Prevention of fat-induced insulin resistance by salicylate. Hundal RS, Petersen KF, Mayerson AB, Rahdhawa PS, Inzucchi S, Shoelson SE, Shulman GI: Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. Hotamisligil GS, Spiegelman BM: Tumor necrosis factor α: a key component of the obesity-diabetes link. Qi C, Pekala PH: Tumor necrosis factor-alpha-induced insulin resistance in adipocytes. Proc Soc Exp Biol Med. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS: Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRSmediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha and obesity-induced insulin resistance. Lowell BB, Shulman GI: Mitochondrial dysfunction and type 2 diabetes. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI: Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI: Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. Li Y, Soos TJ, Li X, Wu J, Degennaro M, Sun X, Littman DR, Birnbaum MJ, Polakiewicz RD: Protein kinase θ inhibits insulin signaling by phosphorylating IRS1 at Ser Bell KS, Shcmitz-Peiffer C, Lim-Fraser M, Biden TJ, Cooney GJ, Kraegen EW: Acute reversal of lipid-induced muscle insulin resistance is associated with rapid alteration in PKC-θ localization. Am J Physiol Endocrinol Metab. Itani SI, Pories WJ, Macdonald KG, Dohm GL: Increased protein kinase C θ in skeletal muscle of diabetic patients. Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM, Olefsky JM, Kobayashi M: A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RE: The TSC1—2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol. Lee YH, Giraud J, Davis RJ, White MF: C-Jun N-terminal kinase JNK mediates feedback inhibition of the insulin signaling cascade. Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR: Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Shepherd PR, Withers DJ, Siddle K: Phosphoinositide 3-kinase: the key switch mechanism in insulin signaling. Terauchi Y, Tsuji Y, Satoh S, Minoura H, Murakami K, Okuno A, Inukai K, Asano T, Kaburagi Y, Ueki K, Nakajima H, Hanafusa T, Matsuzawa Y, Sekihara H, Yin Y, Barrett JC, Oda H, Ishikawa T, Akanuma Y, Komuro I, Suzuki M, Yamamura K, Kodama T, Suzuki H, Kadowaki T: Increased insulin sensitivity and hypoglycaemia in mice lacking the p85α subunit of phosphoinositide 3-kinase. Nat Genet. Ueki K, Algenstaedt P, Mauvais-Jarvis F, Kahn CR: Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85α regulatory subunit. Mauvais-Jarvis F, Ueki K, Fruman DA, Hirshman MF, Sakamoto K, Goodyear LJ, Iannacone M, Accili D, Cantley LC, Kahn CR: Reduced expression of the murine p85α subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. Ueki K, Fruman DA, Yballe CM, Fasshauer M, Klein J, Asano T, Cantley LC, Kahn CR: Positive and negative roles of p85α and p85β regulatory subunits of phosphoinositide 3-kinase in insulin signaling. Barbour LA, Shao J, Qiao L, Leitner W, Anderson M, Friedman JE, Draznin B: Human placental growth hormone increases expression of p85 regulatory unit of phosphatidylinositol 3-kinase and triggers severe insulin resistance in skeletal muscle. Cornier M-A, Bessesen DH, Gurevich I, Leitner JW, Draznin B: Nutritional up-regulation of p85α expression is an early molecular manifestation of insulin resistance. Giorgino F, Pedrini MT, Matera L, Smith RJ: Specific increase in p85α expression in response to dexamethazone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells. Ueki K, Yballe CM, Brachmann SM, Vicent D, Watt JM, Kahn CR, Cantley LC: Increased insulin sensitivity in mice lacking p85β subunit of phosphoinositide 3-kinase. Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC: The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. Barbour L, Rahman SM, Gurevich I, Leitner JW, Fisher S, Roper M, Knotts T, Vo Y, Yakar S, LeRoith D, Kahn CR, Cantley L, Friedman J, Draznin B: Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. Kirwan J, Varastehpour A, Jing M, Presley L, Shao J, Friedman JE, Catalano PM: Reversal of insulin resistance post-partum is linked to enhanced skeletal muscle insulin signaling. JClin Endocrinol Metab. View Metrics. Email alerts Article Activity Alert. Online Ahead of Print Alert. Latest Issue Alert. Most Read Most Cited MRI Metrics of Cerebral Endothelial Cell—Derived Exosomes for the Treatment of Cognitive Dysfunction Induced in Aging Rats Subjected to Type 2 Diabetes. Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel. Genetic Influences of Adiponectin on Insulin Resistance, Type 2 Diabetes, and Cardiovascular Disease. Online ISSN X Print ISSN Books ShopDiabetes. org ADA Professional Books Clinical Compendia Clinical Compendia Home News Latest News DiabetesPro SmartBrief. Resources ADA Professional Membership ADA Member Directory Diabetes. X Twitter Facebook LinkedIn. This Feature Is Available To Subscribers Only Sign In or Create an Account. Close Modal. This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. mTOR 76 — IKK 59 — TNFα 64 — Mitochondrial dysfunction 69 — PKCθ 58 , 72 — Steroids Growth hormone Human placental growth hormone 87 , Short-term overfeeding One of the most important unseen changes? Insulin resistance. Insulin is a key player in developing type 2 diabetes. Here are the high points:. But this finely tuned system can quickly get out of whack, as follows:. Lots of blood sugar in the bloodstream is very damaging to the body and needs to be moved into cells as soon as possible. Yep, weight gain. You do not have to be overweight to have insulin resistance. If you have insulin resistance, you want to become the opposite—more insulin sensitive cells are more effective at absorbing blood sugar so less insulin is needed. These lifestyle changes really work. Talk with your health care provider about how to get started. Skip directly to site content Skip directly to search. Español Other Languages. Insulin Resistance and Diabetes. Spanish Print. Minus Related Pages. Insulin acts like a key to let blood sugar into cells for use as energy. Insulin, Blood Sugar, and Type 2 Diabetes Insulin is a key player in developing type 2 diabetes. Here are the high points: The food you eat is broken down into blood sugar. Blood sugar enters your bloodstream, which signals the pancreas to release insulin. Insulin also signals the liver to store blood sugar for later use. |
| Defining the underlying defect in insulin action in type 2 diabetes | Diabetologia | Hydrating body lotions binding of SH2 domains in the regulatory subunits Inshlin phosphotyrosines on Qnd proteins reduces sognaling constitutive Insulin sensitivity and insulin signaling effects signalingg on the catalytic subunits, leading to increased kinase siignaling towards phosphatidylinositol 4,5-bisphosphate PIP 2 in the plasma membrane, resulting in PIP 3 formation. Updated: 15 February Gupta MK, Vethe H, Softic S et al Leptin receptor signaling regulates protein synthesis pathways and neuronal differentiation in pluripotent stem cells. MAP Kinase Pathways: The First Twenty Years. Increased Energy Expenditure, Decreased Adiposity, and Tissue-Specific Insulin Sensitivity in Protein-Tyrosine Phosphatase 1B-deficient Mice. Diabetes 68 3 — |
| 1 Introduction | Consistent with this, insulin resistance can be identified in offspring of T2D parents many years prior to disease 4. Español Other Languages. F Histogram showing the levels of circulating glucose from larvae expressing UAS-dnEGFR without or with overexpression of Pointed under pumpless-Gal4 control. TATA box-binding protein Tbp was used as housekeeping gene to normalize gene expression. The phosphorylated IRS and SHC proteins bind to growth factor receptor-bound protein 2 GRB2 and then recruit the guanine nucleotide exchange factor, son of sevenless SOS , to activate the RAS—MAPK pathway Mutations of IR are known to cause inherited severe insulin resistance syndromes , but the mechanisms by which these mutations affect IR function have not been systematically explored. |
| Insulin Receptor Signaling in Normal and Insulin-Resistant States | The Phosphoinositide 3-kinase Pathway. Akt-mediated phosphorylation of FOXO1 inhibits its activity by retaining FOXO1 in the cytoplasm , Conversely, expression of a nonphosphorylated form of lipin-1 results in nuclear localization of lipin-1, reduced nuclear SREBP levels, and altered SREBP localization. Silencing of Ndfip1 inhibited cytokine-induced apoptosis of mouse and human pancreatic islets and promoted glucose-stimulated insulin secretion. Ben Vanderkruk, Nina Maeshima, … Brad G. Trends in Biochemical Sciences. Quantitative RT—PCR Total RNA was extracted from S2 cells using QIAGEN RNeasy Mini Kit and treated with On-Column DNase QIAGEN RNase-Free DNase Set at room temperature for 15 min to eliminate genomic DNA contamination. |
| Trends in insulin resistance: insights into mechanisms and therapeutic strategy | The second phase is a slow release of newly formed vesicles that are triggered regardless of the blood sugar level. Glucose enters the beta cells and goes through glycolysis to form ATP that eventually causes depolarization of the beta cell membrane as explained in Insulin secretion section of this article. An increased calcium level activates phospholipase C, which cleaves the membrane phospholipid phosphatidylinositol 4,5-bisphosphate into Inositol 1,4,5-trisphosphate IP3 and diacylglycerol DAG. IP3 binds to receptor proteins in the membrane of the endoplasmic reticulum ER. The process of insulin secretion is an example of a trigger mechanism in a signal transduction pathway because insulin is secreted after glucose enters the beta cell and that triggers several other processes in a chain reaction. While insulin is secreted by the pancreas to lower blood glucose levels, glucagon is secreted to raise blood glucose levels. This is why glucagon has been known for decades as a counter-regulatory hormone. This process is called glycogenolysis. Liver cells, or hepatocytes, have glucagon receptors which allow for glucagon to attach to them and thus stimulate glycogenolysis. When blood glucose levels are too low, the pancreas is signaled to release glucagon, which has essentially the opposite effect of insulin and therefore opposes the reduction of glucose in the blood. Glucagon is delivered directly to the liver, where it connects to the glucagon receptors on the membranes of the liver cells, signals the conversion of the glycogen already stored in the liver cells into glucose. Conversely, when the blood glucose levels are too high, the pancreas is signaled to release insulin. Insulin is delivered to the liver and other tissues throughout the body e. When the insulin is introduced to the liver, it connects to the insulin receptors already present, that is tyrosine kinase receptor. When the insulin binds to these alpha subunits, 'glucose transport 4' GLUT4 is released and transferred to the cell membrane to regulate glucose transport in and out of the cell. With the release of GLUT4, the allowance of glucose into cells is increased, and therefore the concentration of blood glucose might decrease. This, in other words, increases the utilization of the glucose already present in the liver. This is shown in the adjacent image. As glucose increases, the production of insulin increases, which thereby increases the utilization of the glucose, which maintains the glucose levels in an efficient manner and creates an oscillatory behavior. Contents move to sidebar hide. Article Talk. Read Edit View history. Tools Tools. What links here Related changes Upload file Special pages Permanent link Page information Cite this page Get shortened URL Download QR code Wikidata item. Download as PDF Printable version. Human biochemical pathway. Signaling Pathways for Translation: Insulin and Nutrients. ISBN Insulin Action. Review of medical physiology 25th ed. New Delhi: McGraw Hill. Current Diabetes Reviews. doi : PMC PMID Textbook of medical physiology 11th ed. Philadelphia: W. World Journal of Diabetes. S2CID Ronald 8 August Evidence for a potential role for DARPP in insulin action". The Journal of Biological Chemistry. Bibcode : Natur. hdl : Canadian Journal of Physiology and Pharmacology. Current Pharmaceutical Design. Category : Molecular biology. Hidden categories: Articles with short description Short description matches Wikidata Use dmy dates from September Toggle limited content width. In the absence of insulin, FOXO1 translocates to the nucleus where it activates the expression of genes involved in gluconeogenesis, such as phosphoenolpyruvate carboxykinase PEPCK [13]. It also activates the expression of cyclin G2, an atypical cyclin that blocks the cell cycle, which is inhibited by insulin [16] , and appears to play a key role in insulin-induced mitogenesis. When phosphorylated by AKT, FOXO1 is sequestered in the cytoplasm, and therefore cannot activate the expression of its target genes. Importantly, AKT also regulates translocation of the insulin-sensitive glucose transporter GLUT4, which is sequestered in intracellular vesicles of muscle cells and adipocytes to the cell membrane via exocytosis, where it facilitates the uptake of glucose from the blood into cells. This is achieved through the phosphorylation of AS kDa AKT substrate , a GTPase-activating protein that activates RAB, a small G protein involved in membrane trafficking by blocking the exchange of GTP for GDP [17]. The MAPK pathway is an essential secondary branch of the insulin signaling pathway. It is activated independently of the PI3K pathway either through binding of growth factor receptor-bound protein 2 Grb2 to tyrosine-phosphorylated Shc, or through Sh2 binding to the insulin receptor. The amino-terminal SH3 domain of Grb2 binds to proline-rich regions of proteins such as son-of-sevenless SOS , a guanine nucleotide exchange factor that catalyzes the shift of membrane-bound Ras from an inactive form Ras-GDP to an active form Ras-GTP [18]. They act by regulating gene expression as well as extra-nuclear events, such as cytoskeletal reorganization, through the phosphorylation and activation of target proteins in both the cytosol and nucleus [11]. Many mechanisms exist to attenuate, finetune, and terminate insulin signaling, both at the level of the receptor and at various points in the cascade. The insulin receptor and IRS proteins are negatively regulated by multiple systems, such as ligand-induced downregulation, tyrosine protein phosphatases, and serine phosphorylation. Phosphatases also regulate the subsequent steps in the associated protein kinase cascades. Negative feedback loops have been shown to play an essential role in finetuning this complex network [13,2]. Chronic exposure to insulin hyperinsulinemia results in a decrease of insulin receptors on the cell surface [19] , as well as decreased IRS1 and IRS2 in vitro and in vivo in mice, which has been linked to insulin resistance in animal models [13]. The decrease in insulin receptors occurs through endocytosis by clathrin-coated vesicles. These receptors are then recycled or degraded within the lysosomes of the cell [20]. Receptor endocytosis has since been demonstrated to be a critical negative feedback mechanism that is relevant to the entire class of RTKs. IRS signaling is negatively regulated by serine phosphorylation and kinases, such as ERK, S6 kinase, and c-Jun-N-terminal kinase JNK , which are all activated by insulin. This is another negative feedback mechanism in the insulin signaling pathway [13]. The receptor for TNFα TNFR , which predominantly functions in apoptosis and inflammation, induces IRS1 serine phosphorylation through JNK [13] , causing insulin resistance in vitro, and in vivo in animal models as well as humans [21]. PTP1B is a major protein tyrosine phosphatase that dephosphorylates the insulin receptor. This protein resides in the endoplasmic reticulum and acts on the insulin receptor during internationalization and recycling of the receptor to the plasma membrane [22,23]. PTP1B also acts to dephosphorylate residues on activated IGF-1R and IRS proteins to reduce their activity. PTP1B knockout mice have been shown to be more sensitive to insulin and exhibit improved glucose tolerance [24,25]. Protein phosphatase 2A PP2A also plays a critical role in regulating the activities of many protein kinases involved in the insulin cascade, including Akt, PKC, and ERK [27]. Interestingly, PP2A has been demonstrated to be hyperactivated in diabetic states [28]. PH domain leucine-rich repeat protein phosphatases PHLPP-1 and PHLPP-2, members of the PP2C family, act to dephosphorylate both Akt and PKCs [30]. When PHLPP1 is over expressed in cells, the function of Akt and GSK3 activity is reduced. This results in a decrease in glycogen synthesis and glucose transport [31]. Obese and diabetic patients have been shown to have elevated levels of PHLPP1 in both adipose tissue and skeletal muscle which correlates with decreased Akt2 phosphorylation [31,32]. Negative regulation of the PI3K pathway occurs through dephosphorylation and subsequent inactivation of PIP3 by phospholipid phosphatases such as the tumor suppressor PTEN phosphatase and tensin homolog and SHIP2 SH2-containing inositol 5'-phosphatase PTEN dephosphorylates phosphoinositides on the 3'-position, whereas SHIP2 functions at the 5'-position [33]. Suppressor of Cytokine Signaling SOCS proteins also function to attenuate insulin receptor signaling. These are mediators of cytokine receptor signaling, such as leptin and IL-6 receptors that act through Janus kinases JAK and signal transduction, as well as activation of transcription STAT proteins [34,35]. SOCS1, SOCS3, SOCS6, and SOCS7 act by binding to the insulin receptor to inhibit signaling, as well as by targeting IRS-1 and IRS-2 for proteasomal degradation [35]. Type 2 diabetes is the primary disease associated with insulin and the insulin signaling pathways. This complex and heterogeneous disorder is caused by a combination of lifestyle and environmental factors, such as the typical western diet which is high in fats and sugars , inactivity, and obesity, and is further modified by various genetic determinants [36]. Type 2 Diabetes is caused by two factors, insulin sensitivity or insulin resistance attributed to dysregulation of the insulin receptor signaling cascade, and changes in the production and secretion of insulin by the beta cells of the pancreas in response to elevated glucose. However, the relative impact of both defects on the development of diabetes has not yet been ascertained, nor have the specific molecular events at the tissue and cellular level [2]. As insulin receptors are present on many different cell types, dysregulation of the insulin signaling network effects multiple organs of the body in diabetes. Heart attacks and strokes, precipitated by pathological blood clots thrombi , are the leading cause of death in diabetic patients. The reason for this is twofold; firstly, patients with diabetes have an increased risk of developing more extensive atherosclerosis AS [37] , and secondly, they possess "hyperactive" platelets, which are prone to forming thrombi. The rupture of an atherosclerotic plaque, combined with this augmented propensity for platelets to form large occlusive thrombi, increases the risk of fatal thrombotic events in diabetic individuals. Endothelial dysfunction, as well as the hyperactive phenotype of diabetic platelets, are well reported [38,39,40] , but the exact underlying mechanisms remain largely unknown. Diabetic patients also have an increased risk of developing Alzheimer's Disease AD , a neurodegenerative disorder, although the exact relationship between these two diseases is poorly understood. Insulin signaling dysfunction has been reported in the AD brain, however, whether this is a cause or consequence of the disease has not yet been ascertained [41,42]. There is growing evidence that abnormal insulin levels and dysregulated insulin signaling lead to cancer development and progression. A higher incidence of cancer is found in obese patients and those with type 2 diabetes. Many of the proteins that play a role in the insulin signaling pathways are involved in promoting cell proliferation and mitosis, as well as preventing apoptosis, which may increase the risk of tumor formation and metastasis [43]. Despite the tremendous progress made in understanding insulin and insulin receptor signaling over the last decades, there is still much left to be uncovered regarding how these complex networks regulate cells in both normal and disease states. We offer a wide range of research tools that be used for studing the insulin signalling pathway, glucose storage, glucose uptake, and protein lipid synthesis through Ras, Akt, mTor and MAPK. Below we have listed some of our most popular antibodies and immunoassays. The Insulin Receptor The insulin receptor belongs to the superfamily receptor tyrosine kinases RTKs [3,4] and is activated by insulin, as well as insulin-like growth factors IGF Insulin Receptor Pathways When insulin binds to the extracellular α subunits of the insulin receptor, a conformational change is induced, which then results in the autophosphorylation of several tyrosine residues present in the β subunits. Figure 1: The PI3K and MAPK pathways. Negative Regulation of Insulin Receptor Signaling and Signal Termination Many mechanisms exist to attenuate, finetune, and terminate insulin signaling, both at the level of the receptor and at various points in the cascade. Negative Feedback Loops in Response to Insulin Negative feedback loops have been shown to play an essential role in finetuning this complex network [13,2]. Attenuation of Insulin Signaling by Protein and Phospholipid Phosphatases PTP1B is a major protein tyrosine phosphatase that dephosphorylates the insulin receptor. Other Negative Modulators of Insulin Receptor Signaling Suppressor of Cytokine Signaling SOCS proteins also function to attenuate insulin receptor signaling. Figure 3: Negative regulators of the insulin signaling pathway. Dysregulated Insulin Signaling and Disease Type 2 Diabetes Type 2 diabetes is the primary disease associated with insulin and the insulin signaling pathways. Thrombosis and Atherosclerosis Heart attacks and strokes, precipitated by pathological blood clots thrombi , are the leading cause of death in diabetic patients. Cancer There is growing evidence that abnormal insulin levels and dysregulated insulin signaling lead to cancer development and progression. Recommended Products We offer a wide range of research tools that be used for studing the insulin signalling pathway, glucose storage, glucose uptake, and protein lipid synthesis through Ras, Akt, mTor and MAPK. Popular Research Tools. References James, D. et al. Insulin-regulatable Tissues Express a Unique Insulin-Sensitive Glucose Transport Protein. De Meyts, P. The Insulin Receptor and Its Signal Transduction Network. Ullrich, A. Human Insulin Receptor and Its Relationship to the Tyrosine Kinase Family of Oncogenes. Ebina, Y. The Human Insulin Receptor cDNA: The Structural Basis for Hormone-Activated Transmembrane Signalling. Sun, X. Structure of the Insulin Receptor Substrate IRS-1 Defines a Unique Signal Transduction Protein. White, M. and Yenush, L. The IRS-signaling System: A Network of Docking Proteins That Mediate Insulin and Cytokine Action. Current Topics in Microbiology and Immunology. Diabetes 46 , 3—10 Rothman, D. USA 92 , — Cline, G. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. Dresner, A. Effects of free fatty acids on glucose transport and IRSassociated phosphatidylinositol 3-kinase activity. Yu, C. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 IRS-1 -associated phosphatidylinositol 3-kinase activity in muscle. Erion, D. Diacylglycerol-mediated insulin resistance. Kim, J. PKC-theta knockout mice are protected from fat-induced insulin resistance. Nagai, Y. The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. Yen, C. The triacylglycerol synthesis enzyme DGAT1 also catalyzes the synthesis of diacylglycerols, waxes, and retinyl esters. Lipid Res. Timmers, S. Muscular diacylglycerol metabolism and insulin resistance. Liu, L. Upregulation of myocellular DGAT1 augments triglyceride synthesis in skeletal muscle and protects against fat-induced insulin resistance. Sokolowska, E. The Role of Ceramides in Insulin Resistance. Lausanne 10 , Schubert, K. Chaurasia, B. Trends Endocrinol. Stiban, J. Ceramide synthases: roles in cell physiology and signaling. Med Biol. Stöckli, J. Metabolomic analysis of insulin resistance across different mouse strains and diets. Blachnio-Zabielska, A. The crucial role of CCer in fat-induced skeletal muscle insulin resistance. Biochem 40 , — Raichur, S. CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Turpin, S. Obesity-induced CerS6-dependent C ceramide production promotes weight gain and glucose intolerance. Holland, W. An FGFadiponectin-ceramide axis controls energy expenditure and insulin action in mice. Mente, A. Causal relationship between adiponectin and metabolic traits: a Mendelian randomization study in a multiethnic population. PLoS One 8 , e Brown, A. Genetics of Insulin Resistance and the Metabolic Syndrome. Chen, Z. Functional Screening of Candidate Causal Genes for Insulin Resistance in Human Preadipocytes and Adipocytes. Shakhanova, A. Association of polymorphism genes LPL , ADRB2 , AGT and AGTR1 with risk of hyperinsulinism and insulin resistance in the Kazakh population. Henkin, L. Genetic epidemiology of insulin resistance and visceral adiposity. The IRAS Family Study design and methods. Parks, B. Genetic architecture of insulin resistance in the mouse. Xue, A. Genome-wide association analyses identify risk variants and putative regulatory mechanisms for type 2 diabetes. Yousef, A. IRS-1 genetic polymorphism r. Appl Clin. Genet 11 , 99— Hashemian, L. The role of the PPARG Pro12Ala common genetic variant on type 2 diabetes mellitus risk. Zeng, Q. Association Between Insulin-like Growth Factor-1 rs Polymorphism and Type 2 Diabetes Mellitus Susceptibility: A Meta-Analysis. Front Genet 12 , Knowles, J. Identification and validation of N-acetyltransferase 2 as an insulin sensitivity gene. Invest , Richards, J. A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet 5 , e Eichler, E. Missing heritability and strategies for finding the underlying causes of complex disease. Genet 11 , — Flannick, J. Exome sequencing of 20, cases of type 2 diabetes and 24, controls. Nature , 71—76 Viñuela, A. Genetic variant effects on gene expression in human pancreatic islets and their implications for T2D. Metz, S. The Arg82Cys polymorphism of the protein nepmucin implies a role in HDL metabolism. Moltke, I. A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes. Huypens, P. Epigenetic germline inheritance of diet-induced obesity and insulin resistance. Genet 48 , — Ling, C. Epigenetics in human obesity and type 2 diabetes. Ahmed, S. The role of DNA methylation in the pathogenesis of type 2 diabetes mellitus. Epigenetics 12 , 1—23 Cierzniak, A. DNA methylation in adipocytes from visceral and subcutaneous adipose tissue influences insulin-signaling gene expression in obese individuals. Int J. Epigenetic regulation of insulin action and secretion-role in the pathogenesis of type 2 diabetes. Intern Med , — Zhao, J. Global DNA methylation is associated with insulin resistance: a monozygotic twin study. Zhou, Z. DNA methylation landscapes in the pathogenesis of type 2 diabetes mellitus. DNA methylation Landsc. pathogenesis type 2 diabetes Mellit. Liu, J. An integrative cross-omics analysis of DNA methylation sites of glucose and insulin homeostasis. Commu 10 , 1—11 CAS Google Scholar. Gu, T. DNA methylation analysis of the insulin-like growth factor-1 IGF1 gene in Swedish men with normal glucose tolerance and type 2 diabetes. Wittenbecher, C. Insulin-like growth factor binding protein 2 IGFBP-2 and the risk of developing type 2 diabetes. Diabetes 68 , — Haywood, N. Crujeiras, A. Genome-wide DNA methylation pattern in visceral adipose tissue differentiates insulin-resistant from insulin-sensitive obese subjects. Res , 13—24 Ma, X. Functional implications of DNA methylation in adipose biology. Gao, H. Long non-coding RNAs associated with metabolic traits in human white adipose tissue. EBioMedicine 30 , — Altered adipose tissue DNA methylation status in metabolic syndrome: relationships between global DNA methylation and specific methylation at adipogenic, lipid metabolism and inflammatory candidate genes and metabolic variables. Article CAS PubMed Central Google Scholar. Samblas, M. DNA methylation markers in obesity, metabolic syndrome, and weight loss. Epigenetics 14 , — Naidoo, V. Cell-and tissue-specific epigenetic changes associated with chronic inflammation in insulin resistance and type 2 diabetes mellitus. Ali, M. DNA methylation profile of genes involved in inflammation and autoimmunity correlates with vascular function in morbidly obese adults. Epigenetics 17 , 93— Panchal, S. DNA methylation in adipose tissue and metabolic syndrome. Petrus, P. Adipocyte expression of SLC19A1 links DNA hypermethylation to adipose tissue inflammation and insulin resistance. Ramos-Lopez, O. DNA methylation signatures at endoplasmic reticulum stress genes are associated with adiposity and insulin resistance. Genet Metab. Zhang, Y. Methylation of HIF3A promoter CpG islands contributes to insulin resistance in gestational diabetes mellitus. Genet Genom. van Dijk, S. DNA methylation in blood from neonatal screening cards and the association with BMI and insulin sensitivity in early childhood. Endoplasmic reticulum stress epigenetics is related to adiposity, dyslipidemia, and insulin resistance. Adipocyte 7 , — Stillman, B. Histone modifications: insights into their influence on gene expression. Cell , 6—9 Małodobra-Mazur, M. Histone modifications influence the insulin-signaling genes and are related to insulin resistance in human adipocytes. Biochem Cell Biol. Davegårdh, C. DNA methylation in the pathogenesis of type 2 diabetes in humans. David, V. Gluco-incretinsregulate beta-cell glucose competence by epigenetic silencing of fxyd3expression. PLoS ONE 9 , e Emamgholipour, S. Acetylation and insulin resistance: a focus on metabolic and mitogenic cascades of insulin signaling. Lab Sci. Zhou, S. Sirtuins and insulin resistance. Human adipose tissue H3K4me3 histone mark in adipogenic, lipid metabolism and inflammatory genes is positively associated with BMI and HOMA-IR. PloS one 14 , e Maude, H. Epigenetics of Hepatic Insulin Resistance. Cech, T. The noncoding RNA revolution-trashing old rules to forge new ones. Cell , 77—94 Formichi, C. Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases. Ghafouri-Fard, S. The expression profile and role of non-coding RNAs in obesity. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Lausanne 9 , Agbu, P. MicroRNA-mediated regulation of glucose and lipid metabolism. Poy, M. A pancreatic islet-specific microRNA regulates insulin secretion. Jiménez-Lucena, R. Lee, C. Foxa2 controls Pdx1 gene expression in pancreatic β-cells in vivo. Diabetes 51 , — Xu, G. Thioredoxin-interacting protein regulates insulin transcription through microRNA Med 19 , — Bao, L. MicroRNA targets SOCS3 to inhibit beta-cell dysfunction in diabetes. PloS One 10 , e Iacomino, G. Role of microRNAs in obesity and obesity-related diseases. Genes Nutr. Suksangrat, T. miRNA regulation of glucose and lipid metabolism in relation to diabetes and non-alcoholic fatty liver disease. Chen, Y. miRNA inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. Zhou, Y. MicroRNAa induces insulin resistance by targeting PPARδ in skeletal muscle cells. Wang, S. Li, C. Decreased glycogenolysis by miRp promotes regional glycogen accumulation within the spinal cord of amyotrophic lateral sclerosis mice. Front Mol. Zheng, H. MicroRNAp inhibits hepatic gluconeogenesis and reduces fasting blood glucose levels by suppressing G6Pase. Theranostics 11 , Wagschal, A. Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Rayner, K. MiR contributes to the regulation of cholesterol homeostasis. Goedeke, L. MicroRNAa regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Soh, J. MicroRNAc reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Salerno, A. LDL Receptor Pathway Regulation by miR and miRd. Front Cardiovasc Med. Miranda, K. MicroRNA modulates metabolic inflammation by regulating Notch signaling in adipose tissue macrophages. Wang, Y. Natural killer cell-derived exosomal miRp attenuates insulin resistance and inflammation in mouse models of type 2 diabetes. Signal Transduct. Target Ther. Quinn, J. Unique features of long non-coding RNA biogenesis and function. Genet 17 , 47—62 Squillaro, T. Long non-coding RNAs in regulation of adipogenesis and adipose tissue function. Elife 9 , e Zhang, T. Regulation of glucose and lipid metabolism by long non-coding RNAs: facts and research progress. Lausanne 11 , Yang, S. LncRNA SRA deregulation contributes to the development of atherosclerosis by causing dysfunction of endothelial cells through repressing the expression of adipose triglyceride lipase. Med Rep. Zhang, N. Elevated hepatic expression of H19 long noncoding RNA contributes to diabetic hyperglycemia. JCI insight 3 , e Article PubMed Central Google Scholar. Gui, W. LncRNAH19 improves insulin resistance in skeletal muscle by regulating heterogeneous nuclear ribonucleoprotein A1. Cell Commun. Akerman, I. Human pancreatic β cell lncRNAs control cell-specific regulatory networks. Xiong, L. LncRNA-Malat1 is involved in lipotoxicity-induced ß-cell dysfunction and the therapeutic effect of exendin-4 via Ptbp1. Ruan, Y. Circulating LncRNAs analysis in patients with type 2 diabetes reveals novel genes influencing glucose metabolism and Islet β-cell function. Biochem 46 , — Zhang, F. The long non-coding RNA βFaar regulates islet β-cell function and survival during obesity in mice. Li, M. A putative long noncoding RNA-encoded micropeptide maintains cellular homeostasis in pancreatic β cells. Nucleic Acids 26 , — Li, X. The biogenesis, functions, and challenges of circular RNAs. Cell 71 , — Zaiou, M. The emerging role and promise of circular RNAs in obesity and related metabolic disorders. Cells 9 , Stoll, L. A circular RNA generated from an intron of the insulin gene controls insulin secretion. Circular RNAs as novel regulators of β-cell functions in normal and disease conditions. Cai, H. Circular RNA HIPK3 contributes to hyperglycemia and insulin homeostasis by sponging miRp and upregulating transcription factor forkhead box O1. Endocr J. Sun, R. Chen, C. Regulatory roles of circRNAs in adipogenesis and lipid metabolism: emerging insights into lipid-related diseases. FEBS J. Li, A. Identification and characterization of CircRNAs of two pig breeds as a new biomarker in metabolism-related diseases. Biochem 47 , — Arcinas, C. Adipose circular RNAs exhibit dynamic regulation in obesity and functional role in adipogenesis. Lin, X. Front Cell Dev. Li, Q. CircACC1 Regulates Assembly and Activation of AMPK Complex under Metabolic Stress. e7 Du, R. Med 20 , Nayfach, S. New insights from uncultivated genomes of the global human gut microbiome. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature , Derrien, M. The gut microbiota in the first decade of life. Trends Microbiol 27 , — Rinninella, E. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms 7 , 14 David, L. Diet rapidly and reproducibly alters the human gut microbiome. Shi, Z. Gut microbiota: An important link between western diet and chronic diseases. Nutrients 11 , Quiroga, R. Exercise training modulates the gut microbiota profile and impairs inflammatory signaling pathways in obese children. Clauss, M. Interplay between exercise and gut microbiome in the context of human health and performance. Front Nutr. Matenchuk, B. Sleep, circadian rhythm, and gut microbiota. Ramirez, J. Antibiotics as major disruptors of gut microbiota. Front Cell Infect. Microbiol 10 , Awany, D. Host and microbiome genome-wide association studies: current state and challenges. Front Genet 9 , Cahana, I. Impact of host genetics on gut microbiome: Take-home lessons from human and mouse studies. Model Exp. Gut microbiome and its role in obesity and insulin resistance. Gérard, C. Impact of gut microbiota on host glycemic control. Del Chierico, F. Fecal microbiota signatures of insulin resistance, inflammation, and metabolic syndrome in youth with obesity: a pilot study. Acta Diabetol. Wu, H. The gut microbiota in prediabetes and diabetes: a population-based cross-sectional study. Andoh, A. Biochem Nutr. Agus, A. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut 70 , — Martin, A. The influence of the gut microbiome on host metabolism through the regulation of gut hormone release. Scheithauer, T. Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Front Immunol. |
Neugierig topic